Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 183-186

  Alamy, Sayed S ^a   Jarskog, L Fredrik ^a,b,c   Sheitman, Brian B ^a,b   Lieberman, Jeffrey A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Dorothea Dix Hospital   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Autism; Neurodevelopment; Schizophrenia; Secretin; Treatment resistant

Indexed keywords

CLOZAPINE; FLUPHENAZINE; GASTROINTESTINAL POLYPEPTIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SECRETIN;

ADULT; ANAMNESIS; ARTICLE; AUTISM; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG INDICATION; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 0346786360     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2003.07.003     Document Type: Article

References (24)

1. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 25:2001;1-27.
2. Campbell M., Shay J. Pervasive developmental disorders. Kaplan H.I., Sadock B.J. Comprehensive Textbook of Psychiatry. 6th ed. 1995;2277-2293 Williams and Wilkins, New York.
3. Carpenter W.T. Jr., Buchanan R.W. Schizophrenia: introduction and overview. Kaplan H.I., Sadock B.J. Comprehensive Textbook of Psychiatry. 6th ed. 1995;889-1018 Williams and Wilkins, New York.
4. Chez M.G., Buchanan C.P., Bagan B.T., Hammer M.S., McCarthy K.S., Ovrutskaya I., Nowinski C.V., Cohen Z.S. Secretin and autism: a two part clinical investigation. J. Autism Dev. Disord. 30:2000;87-94.
5. de Lecea L., Kilduff T.S., Peyron C., Gao X.-B., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L.F., Gautvik V.T., Bartlett F.S. II, Frankel W.N., van den Pol A.N., Bloom F.E., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 95:1998;322-327.
6. Fatemi S.H., Halt A.R. Altered levels of Bcl2 and p53 proteins in parietal cortex reflect deranged apoptotic regulation in autism. Synapse. 42:2001;281-284.
7. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 57:2000;65-73.
8. Horrobin D.F. Schizophrenia: a biochemical disorder? Biomedicine. 32:1980;54-55.
9. Horvath K., Stefanatos G., Sokolski K.N., Wachtel R., Nabors L., Tildon J.T. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Physicians. 9:1998;9-15.
10. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry. 48:2000;641-650.
11. Kanner L. Autistic disturbances of affective contact. Nerv. Child. 2:1943;217-250.
12. Kemper T.L., Bauman M. Neuropathology of infantile autism. J. Neuropathol. Exp. Neurol. 57:1998;645-652.
13. Kern J.K., Miller V.S., Evans P.A., Trivedi M.H. Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J. Autism Dev. Disord. 32:2002;153-160.
14. Lord C., Cook E.H., Leventhal B.L., Amaral D.G. Autism spectrum disorders. Neuron. 28:2000;355-363.
15. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., Shenton M.E. MRI anatomy of schizophrenia. Biol. Psychiatry. 45:1999;1099-1119.
16. 125I-secretin receptor binding sites in rat brain. Biochem. Biophys. Res. Commun. 292:2002;133-137.
17. Piven J., Arndt S., Bailey J., Havercamp B.S., Andreasen N.C., Palmer P. An MRI study of brain size in autism. Am. J. Psychiatry. 152:1995;1145-1149.
18. Raymond G.V., Bauman M.L., Kemper T.L. Hippocampus in autism: a Golgi analysis. Acta Neuropathol. 91:1996;117-119.
19. Rivto E.R., Freeman B.J., Schweibel A.B., Duong T., Robinson H., Guthrie D., Rivto A. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC autopsy research report. Am. J. Psychiatry. 143:1986;862-866.
20. Sandler A.D., Sutton K.A., DeWeese J., Girardi M.A., Sheppard V., Bodfish J.W. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N. Engl. J. Med. 341:1999;1801-1806.
21. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818.
22. Sheitman B.B., Knable M., Jarskog L.F., Chakos M., Boyce L.H., Early J., Lieberman J.A. Secretin for refractory schizophrenia. Schizophr. Res. 66:2003;177-181.
23. Whiteley P., Shattock P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin. Ther. Targets. 6:2002;175-183.
24. Wright I.C., Ellison Z.R., Sharma T., Friston K.J., Murray R.M., McGuire P.K. Mapping grey matter changes in schizophrenia. Schizophr. Res. 35:1999;1-14.